[Event Report] Non-partisan Diet Member Briefing – Creating Pull Incentives to Spur the Development of Antimicrobials (April 22, 2021)
date : 4/22/2021
Tags: AMR, Diet Member Briefing
AMR Alliance Japan held a Diet Member briefing about “Creating Pull Incentives to Spur the Development of Antimicrobials.”
Despite the growing threat of antimicrobials resistance (AMR) – the natural process by which the germs that cause infectious disease grow immune to existing antimicrobials over time – the world has seen a decline in the development of novel antimicrobials since the 1980s.
This problem has arisen from a market failure. It can take 10-15 years and over US$1 billion to develop an antimicrobial. Once an antimicrobial is approved for use, it is important to take care not to overuse it. As a result, new antimicrobials typically see low sales, and companies face problems in covering post-approval costs. This issue has led to the collapse of multiple companies that developed antimicrobials in recent years.
AMR Alliance Japan (Secretariat: Health and Global Policy Institute) has been serving as secretariat for the Nikkei FT Communicable Diseases Conference Asia Africa Asia Medical Innovation Consortium (AMIC) AMR Consortium. The AMR Consortium has developed recommendations on “pull incentives” for antimicrobial development that could solve the above issues.
For this Diet Briefing, HGPI invited two speakers to discuss the realization of pull incentives in Japan. Afterward, there was a question and answer session with the Diet Members.
Recommendations on Pull Incentives for AMR in Japan Executive Summary
■Program
Explanatory Introduction
Matt McEnany (Senior Manager, HGPI)
Presentation 1
“The Threat of AMR and the Need for Countermeasures”
Dr. Norio Ohmagari (Director of the AMR Clinical Reference Center and Director of the Disease Control and Prevention Center of the National of Center for Global Health and Medicine (NCGM))
Presentation 2
“Recommendations from the AMR Consortium: Realizing a Pull Incentive”
Dr. Kazumasa Oguro (Professor, Faculty of Economics, Hosei University)
【About AMR Alliance Japan】
AMR Alliance Japan was established in November 2018 as multi-stakeholder, collaborative organization dedicated to the improvement of public health through the promotion of AMR countermeasures. As of June 2021, its members include, in alphabetical order: The Japan Medical Association; The Japan Pharmaceutical Association; The Japan Pharmaceutical Manufacturers Association; The Japan Society of Hospital Pharmacists; The Japanese Association for Infectious Diseases; The Japanese Society for Chemotherapy; The Japanese Society for Clinical Microbiology; The Japanese Society for Medical Mycology; The Japanese Society for Pediatric Infectious Diseases; The Japanese Society of Infection Prevention and Control; The Japanese Society of Pharmaceutical Health Care and Sciences; The Japanese Society of Therapeutic Drug Monitoring; MSD K.K.; Shionogi & Co., Ltd.; Nippon Becton Dickinson Co., Ltd.; Pfizer Inc.; The Pharmaceutical Society of Japan. The Health and Global Policy Institute serves as the Secretariat of AMR Alliance Japan.
日本語
Top Research & Recommendations Posts
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Publication Report] Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government (March 31, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Research Report] Healthcare DX Project Research Report of Interviews ”Expectations for the Coming Era of Healthcare DX from People Living with Health Concerns” (June 10, 2024)
- [Policy Recommendations] Recommendation for the Basic Policy on Economic and Fiscal Management and Reform 2024 (June 11, 2024)
- [Policy Recommendations] Kidney Disease Control Promotion Project 2023 “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” Policy Recommendations, a Collection of Good Practices of Chronic Kidney Disease (CKD) and Control Measures in Local Governments (February 14, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Public Comment Submission] Web based consultations on NCDs and mental health by World Health Organization (June 25, 2024)
- [Research Report] 2019 Survey on Healthcare in Japan
Featured Posts
-
2024-06-21
[Event Report] HGPI Special Seminar – HGPI Celebrates its 20th Anniversary: Reflecting on HGPI’s Journey from the Past to the Future (January 16, 2024)
-
2024-06-25
[Public Comment Submission] Web based consultations on NCDs and mental health by World Health Organization (June 25, 2024)
-
2024-06-26
[Event Report] Global Expert Meeting “Innovation in Cancer Care in Developing Countries ~City Cancer Challenge Initiatives“ (June 20, 2024)
-
2024-06-26
[Registration Open] (Webinar) The 127th HGPI Seminar: Current Issues and Future Prospects in Establishing a Health System and Protecting Public Health Through Policy (July 18, 2024)
-
2024-07-01
[Registration Open] Meaningful Involvement Promotion Project Online Expert Meeting “Shaping the Future of Health Policy with People with Lived Experience and Citizens” (July 26, 2024)